Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 9/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4776472 | 0.96 | ACVR2A (0.34) | MAT2ATGFBR1ADORA2AADORA3ADORA1 | |
| SCHEMBL4770172 | 0.87 | MAT2A (0.37) | MAT2ATGFBR1PTGER3 | |
| SCHEMBL4770164 | 0.87 | MAT2A (0.37) | MAT2ATGFBR1PTGER3 | |
| SCHEMBL4775034 | 0.87 | MAT2A (0.34) | MAT2ATGFBR1ADORA2AADORA3ADORA1 | |
| SCHEMBL4775031 | 0.87 | MAT2A (0.34) | MAT2ATGFBR1ADORA2AADORA3ADORA1 | |
| SCHEMBL4778624 | 0.85 | MAPT (0.36) | MAT2ATGFBR1ADORA2AADORA3ADORA1 | |
| SCHEMBL4769886 | 0.84 | MAT2A (0.34) | MAT2A | |
| SCHEMBL4769879 | 0.84 | MAT2A (0.34) | MAT2A | |
| SCHEMBL4778910 | 0.82 | ADORA3 (0.35) | MAT2AADORA2AADORA3ADORA1LRRK2 | |
| SCHEMBL4774982 | 0.82 | PSEN1 (0.35) | MAT2AADORA2AADORA3ADORA1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459451-B2 | e.g. 1-Ethyl-4-(5-methyl-3-pyridyl)-6-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid; phosphodiesterase (PDE)-IV inhibitor or tumor necrosis factor (TNF)- alpha antagonist; autoimmune diseases, antidepressant, anxiolytic agent; polychondritis, scleroderma, fibrosis, arthritis, Alzheimer's disease | ASTELLAS PHARMA INC. (JP) | 2008-12-02 | — | — | US | disclosed |
| EP-1763528-B1 | PYRAZOLOPYRIDINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-11-26 | — | — | EP | disclosed |
| EP-1763528-A1 | PYRAZOLOPYRIDINE DERIVATIVES | Astellas Pharma Inc. (JP) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006004188-A1 | PYRAZOLOPYRIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004003-A1 | Pyrazolopyridine derivatives | ASTELLAS PHARMA INC. (JP) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004003-A1 | Pyrazolopyridine derivatives | PDE4A, PDE3B, PDE5A | MAT2A 3361/4885TGFBR1 212/4885ADORA2A 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.